Sian Bigora - 31 Dec 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Development Officer
Signature
/s/ Sian Bigora by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
4
Filing time
04 Jan 2023, 16:38:37 UTC
Previous filing
03 Oct 2022
Next filing
12 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +13,851 +4% $0.000000 356,073 31 Dec 2022 Common Stock 13,851 $0.000000 Direct F1
transaction PCSA Restricted Stock Units Award $0 +75,907 +21% $0.000000 431,985 01 Jan 2023 Common Stock 75,907 $0.000000 Direct F2
transaction PCSA Restricted Stock Units Award $0 +48,490 +11% $0.000000 480,475 01 Jan 2023 Common Stock 48,490 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.
F2 Each restricted stock units represents a contingent right to receive one share of stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.
F3 Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.